#TempleHealth Researchers have identified a critical genetic mechanism driving cardiac fibrosis and a novel target, ACLY, for reversing it. This could pave the way for new therapies to combat heart failure. Learn more:
#TempleMed scientists led by John Elrod, Director Aging + Cardiovascular Discovery Center and Professor of Cardiovascular Sciences, have discovered a critical genetic mechanism driving the process of cardiac fibrosis — and identified a novel target for reversing it. The research was funded in part by grants from the The National Institutes of Health and the American Heart Association. Learn more about the findings at https://lnkd.in/ed892pHy